CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN – Get Free Report) traded down 1.9% during mid-day trading on Monday. The company traded as low as $3.45 and last traded at $3.56. Approximately 28,969 shares changed hands during trading, a decline of 49% from the average session volume of 57,075 shares. The stock had previously closed at $3.63.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CollPlant Biotechnologies in a report on Friday, September 4th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, CollPlant Biotechnologies presently has a consensus rating of “Reduce” and a consensus target price of $120.00.
View Our Latest Stock Report on CollPlant Biotechnologies
CollPlant Biotechnologies Stock Performance
The firm has a market capitalization of $6.73 million, a P/E ratio of -0.26 and a beta of 1.77. The firm’s 50-day moving average is $3.57 and its 200 day moving average is $3.65.
CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) last announced its earnings results on Wednesday, September 30th. The company reported ($1.89) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.45) by $0.56. The firm had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.48 million. CollPlant Biotechnologies had a negative net margin of 678.37% and a negative return on equity of 298.21%.
About CollPlant Biotechnologies
CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is an Israel-based biotechnology company developing regenerative medicine products and tissue-engineering technologies. The company’s platform uses genetically engineered tobacco plants to produce recombinant human collagen (rhCollagen), a purified collagen material designed to support the repair, replacement, and regeneration of human tissue.
CollPlant develops rhCollagen-based products for applications including 3D bioprinting, tissue engineering, and advanced wound care.
Further Reading
- Five stocks we like better than CollPlant Biotechnologies
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
